Carboplatin, Paclitaxel, and Pembrolizumab
About
Membership operator: AND
Therapies: 3
Therapies
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy group.
Organizations
Biomarkers
Cancer types
Therapies
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| EMA (1) FDA (2) | PD-L1 (CPS) >= 1 | Cervical Adenocarcinoma | Carboplatin, Paclitaxel, Pembrolizumab | |
| FDA (2) | PD-L1 (CPS) >= 1 | Cervical Squamous Cell Carcinoma | Carboplatin, Paclitaxel, Pembrolizumab | |
| EMA (1) | Wild type ALK, Wild type EGFR | Non-Small Cell Lung Cancer | Carboplatin, Paclitaxel, Pembrolizumab |